Neuropathic pain associated with spinal cord injury is caused by complex neural mechanisms and is often refractory to standard therapy. Salmon calcitonin was an effective treatment for neuropathic symptoms in this case series of three patients with recent spinal cord injury. Salmon calcitonin is already used to help manage pain after limb amputation and also after vertebral fractures and it is perhaps surprising that it has not been trialled previously for spinal cord injury pain. Calcitonin is thought to exert its effect by modulation of the serotonergic system and is generally well tolerated and convenient to administer. This underutilised drug may be a very useful adjuvant for neuropathic pain associated with spinal cord injury.
JaegerH., MaierC.Calcitonin in phantom limb pain: a doubleblind study.Pain1992; 48: 21–27.
2.
VisserE.J.A review of calcitonin and its use in the treatment of acute pain.Acute Pain2005; 7: 185–189.
3.
VisserE.J., KweiP.L.Salmon calcitonin in the treatment of post herpetic neuralgia.Anaesth Intensive Care2006; 34: 668–671.
4.
ClementiG., Amico-RoxasM., RapisardaE., CarusoA., PratoA., TrombadoreS.The analgesic activity of calcitonin and the central serotonergic system.Eur J Pharmacol1985; 108: 71–75.
5.
QueJ.C., SiddallP.J., CousinsM.J.Pain management in a patient with intractable spinal cord injury pain: a case report and literature review.Anesth Analg2007; 105: 1462–1473.
6.
SiddallP.J., MiddletonJ.W.A proposed algorithm for the management of pain following spinal cord injury.Spinal Cord2006; 44: 67–77.
7.
MaciasM.Y., SyringM.B., PizziM.A., CroweM.J., AlexanianA.R., KurpadS.N.Pain with no gain: allodynia following neural stem cell transplantation in spinal cord injury.Exp Neurol2006; 201: 335–348.
8.
SiddallP.J., YezierskiR.P., LoeserJ.D.Taxonomy and epidemiology of spinal cord injury pain. In: BurchielK.J., YezierskiR.P., eds. Spinal Cord Injury Pain: Assessment, Mechanisms, Management. Progress in Pain Research and Management. Vol. 23. Seattle, IASP Press2002. p. 9–24.
9.
SiddallP.J., CousinsM.J., OtteA., GriesingT., ChambersR., MurphyT.K.Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial.Neurology2006; 67: 1792–1800.
10.
GanongW.F.Review of Medical Physiology, 22nd ed.Appleton & Lange, East Norwalk, Connecticut2005.
11.
AzriaM.Possible mechanisms of the analgesic action of calcitonin.Bone2002; 30: 80S–83S.
12.
LyritisG.P., TrovasG.Analgesic effects of calcitonin.Bone2002; 30: 71S–74S.
13.
OrmazabalM.J., GoicoecheaC., AlfaroM.J., SanchezE., MartinM.I.Study of mechanisms of calcitonin analgesia in mice. Involvement of 5-HT3 receptors.Brain Res1999; 845: 130–138.
14.
ColadoM.I., OrmazabalM.J., GoicoecheaC., LopezF., AlfaroM.J., MartinM.I.Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse.Eur J Pharmacol1994; 252: 291–297.
15.
CeseraniR., ColomboM., OlgiatiV.R., PecileA.Calcitonin and prostaglandin system.Life Sci1979; 25: 1851–1855.
16.
MartinM.I., GoicoecheaC., ColadoM.I., AlfaroM.J.Analgesic effect of salmon-calcitonin administered by two routes. Effect on morphine analgesia.Eur J Pharmacol1992; 224: 77–82.
17.
WelchS.P., CooperC.W., DeweyW.L.Antinociceptive activity of salmon calcitonin injected intraventricularly in mice: modulation of morphine antinociception.J Pharmacol Exp Ther1986; 237: 54–58.
AppelboomT.Calcitonin in reflex sympathetic dystrophy syndrome and other painful conditions.Bone2002; 30: 84S–86S.
20.
PerezR.S., KwakkelG., ZuurmondW.W., de LangeJ.J.Treatment of reflex sympathetic dystrophy (CRPS type 1): a research synthesis of 21 randomized clinical trials.J Pain Symptom Manage2001; 21: 511–526.
21.
GobeletC., WaldburgerM., MeierJ.L.The effect of adding calcitonin to physical treatment on reflex sympathetic dystrophy.Pain1992; 48: 171–175.
22.
BickerstaffD.R., KanisJ.A.The use of nasal calcitonin in the treatment of post-traumatic algodystrophy.Br J Rheumatol1991; 30: 291–294.
IsbisterG.K., BuckleyN.A.The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment.Clin Neuropharmacol2005; 28: 205–214.
